AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals
The AMR Action Fund, the world’s largest public-private partnership investing in biotech companies that are developing antibiotics, announced today that it has invested in Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals. The transactions mark the Fund’s first investments and are an important step toward its goals of bringing to market new treatments for priority pathogens identified by the World Health Organization (WHO) and U.S. Centers for Disease Control and Prevention.
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!